Triple-Negative Breast Cancer (TNBC) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Triple-Negative Breast Cancer Emerging Therapy and TPP Insights

Thelansis's "Triple-Negative Breast Cancer (TNBC) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Triple-Negative Breast Cancer Overview

Triple-negative breast cancer (TNBC) is defined by negative estrogen- and progesterone-receptor tests and HER2-negative testing. Course varies by stage and tumor biology, and some tumors recur early. Localized disease is treated with chemotherapy and surgery; pembrolizumab may be added for eligible high-risk cases. In metastatic disease, treatment depends on PD-L1 expression, germline BRCA1/2 status, prior therapy, and fitness. Options include pembrolizumab with chemotherapy for PD-L1 CPS >=10 tumors and PARP inhibitors for selected germline BRCA-mutated cancers. In 2026 the FDA approved first-line sacituzumab govitecan alone for patients unsuitable for checkpoint inhibitors, and with pembrolizumab for PD-L1 CPS >=10 disease. Datopotamab deruxtecan was also approved for metastatic TNBC when PD-1/PD-L1 therapy is unsuitable. Resistance and relapse remain challenges, sustaining research into antibody-drug conjugates and biomarker-guided combinations. Ongoing trials are a research priority.

Key Highlights

• In Spain, TNBC incident cases are projected to increase from 2,778 in 2026 to 2,899 by 2036.
• TNBC is an aggressive breast cancer subtype with limited targeted treatment options.
• Higher risk of recurrence and metastasis remains a major clinical challenge.
• Significant unmet need remains for durable and effective treatment options.

Market Overview

• The Germany TNBC market is projected to grow from $330M in 2026 to $785M by 2036.
• Market growth is driven by:
• Increasing adoption of immunotherapy and targeted treatment approaches
• Continued development of novel TNBC therapies
• Future growth will depend on therapies that improve durable responses and long-term outcomes.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• AstraZeneca
• Merck Sharp & Dohme LLC
• Seagen Inc.
• Hoffmann-La Roche
• Telomir Pharmaceuticals, Inc.
• Cantargia AB
• Gilead Sciences
• Jina Pharmaceuticals Inc.
• BioLite, Inc.
• OBI Pharma, Inc.
• SURGE Therapeutics
• Qilu Pharmaceutical Co., Ltd.
• Akeso
• BioNTech SE
• CoRegen, Inc.
• MedSIR
• Beijing Biotech
• Adcentrx Therapeutics
• NiKang Therapeutics, Inc.
• Pfizer
• Daiichi Sankyo Co., Ltd.
• Eli Lilly and Company
• Novartis Pharmaceuticals
• Accent Therapeutics
• SillaJen, Inc.
• Apollo Therapeutics Ltd
• Radiopharm Theranostics, Ltd.
• Normunity AccelCo, Inc.
• Genentech, Inc.
• AbbVie
• Genmab
• IDEAYA Biosciences
• Arcus Biosciences, Inc.
• Immunitas Therapeutics
• Exelixis
• Incyte Corporation
• OncoNano Medicine, Inc.